What is Clex Bio?
Headquartered in Norway, Clex Bio operates at the intersection of biotechnology and material science. The company specializes in developing breakthrough solutions for tissue engineering and single-cell analysis. Central to its technological portfolio is the proprietary hydrogel platform known as CLEX, which enables precise bio-fabrication capabilities. By integrating these advanced techniques, Clex Bio is addressing critical gaps in regenerative medicine and cellular research, positioning itself as a high-growth entity within the European biotech ecosystem.
How much funding has Clex Bio raised?
Clex Bio has raised a total of $2.2M across 1 funding round:
Angel/Seed
$2.2M
Angel/Seed (2021): $2.2M, investors not publicly disclosed
Key Investors in Clex Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Clex Bio?
With the infusion of this recent capital, Clex Bio is expected to transition from its foundational research phase into a more robust commercialization strategy. The company will likely focus on scaling its proprietary hydrogel production and expanding its clinical partnerships to validate its tissue engineering models. As the firm matures, the strategic deployment of these funds will be essential for navigating the complex regulatory landscape of the biotech sector and securing a competitive advantage in the global market for advanced cellular therapies.
See full Clex Bio company page
